糖共传输体-2 抑制剂和心脏病:当前的前景
Sunetra Mondal1, Subhodip Pramanik2, Vibhu Ranjan Khare1
1Department of Endocrinology, NRS Medical College, Kolkata 700020, West Bengal, India.
World journal of cardiology
|May 31, 2024
概括
葡萄糖携运输体-2 抑制剂 (SGLT-2i) 除了糖尿病管理之外,还能为心血管提供显著的益处. 这些药物对于预防和治疗糖尿病和非糖尿病患者的心血管疾病 (CVD) 至关重要.
科学领域:
- 药理学和心脏病学 药理学和心脏病学
- 内分泌学和脏学.
背景情况:
- 葡萄糖携带载体-2 抑制剂 (SGLT-2i) 是已确定的抗糖尿病药物.
- 多项研究表明,SGLT-2i具有显著的心血管 (CV) 益处.
- 这些好处超出了糖尿病患者的血糖控制范围.
研究的目的:
- 审查目前关于SGLT-2i在心血管疾病 (CVD) 预防和管理中的作用的证据.
- 阐明SGLT-2i.的器官保护作用背后的分子机制.
- 为心脏病专家和其他专家指导SGLT-2i在临床实践中的合理使用.
主要方法:
- 从随机对照试验和真实世界的数据收集证据.
- 对SGLT-2i的器官保护作用背后的分子机制的审查.
- 临床综述侧重于患者护理中的实际应用.
主要成果:
- 在患有和没有糖尿病的患者中,SGLT-2i显示出显著的心血管益处.
- 这些药物在预防和管理非糖尿病心血管和病方面表现出有效性.
- 目前正在进行的研究正在阐明涉及的多种分子通路.
结论:
- SGLT-2i具有重要的器官保护性质,独立于它们的抗糖尿病作用.
- 了解这些机制对于优化SGLT-2i在心血管和脏护理中的使用至关重要.
- 本综述为管理心血管疾病或心血管疾病风险患者的临床医生提供了全面的概述.
相关概念视频
Glucose Transporters
22.7K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.7K
Secondary Active Transport
119.3K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
119.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones
189
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
189
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
173
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
173
Glucose Absorption Into the Small Intestine
31.6K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.6K
Heart Failure Drugs: Inotropic Agents
570
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
570


